THERAKOS® CELLEX® Photopheresis System

THERAKOS® CELLEX® Photopheresis System

Therakos Cellex delivers a fully integrated, automated extracorporeal photopheresis (ECP) system, providing superior efficiency, safety, and patient outcomes.

Key advantages:

  • Faster treatment times(1):
    • Single-needle mode: 105 mins/Treatment
    • Double-needle mode: 75 mins/Treatment
  • Only Online, integrated device to be approved by both FDA and EU certified.
  • Workday Limitation: Based on a 7.5-hour workday (450 minutes)(2), integrated systems triple patient throughput, maximizing efficiency and bed utilization in clinical settings.
  • Compact and integrated system that enhances mobility.
  • Single machine performs cell collection, ECP treatment and reinfusion of treated blood back to the patient, thus reducing the hidden cost.
  1. Data on file. Ref-01420. Mallinckrodt Pharmaceuticals.
  2. Azar N, Leblond V, Ouzegdouh M, Button P. A transition from using multi-step procedures to a fully integrated system for performing extracorporeal photopheresis: A comparison of costs and efficiencies. J Clin Apher. 6 2017 Dec;32(6):474-478. doi: 10.1002/jca.21542. Epub 2017 Apr 17. PMID: 28419561; PMCID: PMC5724655

    Value Proposition

    Cellex as the only connected device requiring no additional machines.

    Cellex’s 90-minute treatment turnaround time.

    100 Reduced Hospital Stays
    500 Improved Transplant Outcomes
    4200 Smiling Customer

    How the THERAKOS CELLEX System Works:

    1. Blood Collection:
      • The patient’s blood is drawn, and the white blood cells (including T cells) are separated from the rest of the blood using centrifugation.
    2. Photoactivation:
      • A photosensitizing agent, such as 8-methoxypsoralen (8-MOP), is introduced. This agent makes T cells sensitive to ultraviolet A (UVA) light.
      • The separated white blood cells are then exposed to UVA light, which damages the DNA of the treated cells, rendering them apoptotic (programmed cell death).
    3. Reinfusion:
      • The treated white blood cells are reinfused back into the patient, where they induce an immunomodulatory effect by stimulating regulatory T cells (Tregs) and reducing inflammation or abnormal immune responses.

        With faster treatment times, continuous operation, and advanced customization, Cellex reduces manual errors, increases patient throughput, and ensures precision for personalized care setting the standard for modern photopheresis systems.

        Our THERAKOS® CELLEX® Customers

        Our customers are the pillars of our strength and motivation to strive for a better tomorrow.

        Dr. Swaminathan

        Utilized machine on more than 10 marginal organs (both liver and kidney). Vitasmart benefits lots of patients by transplanting them with Marginal organs which otherwise would have been discarded

        Dr. Prabhu Kanchi

        There are very less incidences of DGF, PNF and low rejection rates compared to static cold storage

        Dr. Elankumaran K

        Extended criteria organs were allocated to the patients benefited with shorter hospital stay

        John M Kenedy

        Far far away, behind the word mountains, far from the countries Vokalia and Consonantia, there live the blind texts.

        Arjun Pandit

        Even the all-powerful Pointing has no control about the blind texts it is an almost unorthographic life One day however a small line of blind text by the name of Lorem Ipsum decided to leave for the far World of Grammar.

        Global Partnerships

        Latest Blogs

        Our latest published articles

        Interested to know more?

        To learn more about Duraent's innovative organ preservation solutions and transplant technologies, contact us. Discover how we empower medical professionals to deliver life-saving results through groundbreaking products like VitaSmart™ and Belzer UW® Cold Storage Solution.

        Request a Demo